Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2019 Apr 1;17(4):367-402.
doi: 10.6004/jnccn.2019.0018.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Daniel G Coit  1 , John A Thompson  2 , Mark R Albertini  3 , Christopher Barker  1 , William E Carson  4 , Carlo Contreras  5 , Gregory A Daniels  6 , Dominick DiMaio  7 , Ryan C Fields  8 , Martin D Fleming  9 , Morganna Freeman  10 , Anjela Galan  11 , Brian Gastman  12 , Valerie Guild  13 , Douglas Johnson  14 , Richard W Joseph  15 , Julie R Lange  16 , Sameer Nath  17 , Anthony J Olszanski  18 , Patrick Ott  19 , Aparna Priyanath Gupta  20 , Merrick I Ross  21 , April K Salama  22 , Joseph Skitzki  23 , Jeffrey Sosman  20 , Susan M Swetter  24 , Kenneth K Tanabe  25 , Evan Wuthrick  26 , Nicole R McMillian  27 , Anita M Engh  27
Affiliations
Practice Guideline

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Daniel G Coit et al. J Natl Compr Canc Netw. .

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes the data and rationale supporting extensive changes to the recommendations for systemic therapy as adjuvant treatment of resected disease and as treatment of unresectable or distant metastatic disease.

PubMed Disclaimer

Publication types